WHO ICTRP trial
Diagnostic Accuracy of 68Ga-PSMA PET/CT to identify residual Prostate Cancer…
ACTRN12623001082695 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12623001082695 |
|---|---|
| Public title | Diagnostic Accuracy of 68Ga-PSMA PET/CT to identify residual Prostate Cancer Following Focal therapy with Irreversible Electroporation (NanoKnife). |
| Scientific title | Diagnostic Accuracy of 68Ga-PSMA PET/CT to identify residual Prostate Cancer Following Focal therapy with Irreversible Electroporation for localized Prostate Cancer: A Prospective Study |
| Primary sponsor | St Vincent's Private Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Australia |
| Conditions | Prostate Cancer; Prostate Cancer;Cancer - Prostate |
| Interventions | The PET tracer, 68Ga-PSMA, is a PSMA ligand radiolabelled with Gallium-68 to enable its use for PET imaging which is intravenously injected in patients prior to the scan (289.9 to 414 MBq ). This whole process can take up to an hour to… |
| Registration date | Dec 10, 2023 |
| Target size | 154 |
| Secondary IDs | Nil known |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: